Related Experiment Video

Updated: Aug 15, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

A small molecule compound inhibits AKT pathway in ovarian cancer cell lines

Huai-Jing Tang1, Xiaohong Jin, Shaomeng Wang

  • 1Department of Obstetrics and Gynecology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA.

Gynecologic Oncology
|October 8, 2005
PubMed
Abstract

Insights

A novel compound, API-59-OME, effectively inhibits the AKT pathway in ovarian cancer cells, inducing apoptosis. This targeted approach shows promise for treating ovarian carcinoma by blocking cancer cell survival signals.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Overactivation of AKT1 and gene amplification of AKT2 are common in ovarian cancer, promoting cancer cell survival and resistance to therapy.
  • The AKT pathway is a key mediator of cell survival, making it a critical target for ovarian cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of API-59-OME, a novel small molecule inhibitor, in targeting the AKT pathway in ovarian cancer.
  • To determine if API-59-OME can induce apoptosis in ovarian cancer cells by inhibiting AKT kinase activity.

Main Methods:

  • Ovarian cancer cell lines (A2780, MDAH2774, OVCAR-8, Caov-3) and murine fibroblasts (NIH3T3) were treated with API-59-OME.
  • Kinase assays were performed to assess the inhibition of AKT and other kinases, as well as downstream signaling.
  • Apoptosis induction was measured via poly (ADP-ribose) polymerase (PARP) cleavage and sub-G1 DNA content analysis.

Main Results:

  • API-59-OME selectively inhibited AKT kinase activity in ovarian cancer cell lines with elevated phosphorylated AKT.
  • The compound induced apoptosis and PARP cleavage in these sensitive cell lines.
  • API-59-OME showed minimal apoptotic effect in cell lines lacking constitutive AKT activity.

Conclusions:

  • API-59-OME demonstrates potent activity against ovarian cancer cells by targeting the constitutively activated AKT pathway.
  • These findings suggest API-59-OME as a potential therapeutic agent for ovarian carcinoma.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...